Batavia Biosciences Increases Capacity for Viral Vectors and Vaccine R&D in the Netherlands
Batavia Biosciences is expanding its headquarters and R&D capabilities in its Netherlands facility.
Batavia Biosciences announced the expansion of its headquarters and R&D capacity in its Netherlands facility on June 14, 2022. The 22,500-ft² expansion will increase R&D activities for viral vector-based product development, including Lentivirus, adeno-associated virus (AAV), adenovirus, and measles virus vectors. The expansion is expected to be finalized by June 2023.
“The new laboratory floor space for R&D and analytical capabilities will aid the development capacity for customer projects,” said Chris Yallop, chief scientific officer, Batavia Biosciences, in a company press release. “The increased allocation for R&D capacity better positions Batavia Biosciences to serve as pacemakers to the community and to continue to bring promising candidate biopharmaceuticals from bench to clinic.”
According to a company press release, the increased R&D infrastructure is intended to meet increased global development for vaccine development, including live-attenuated, whole killed, vectored, or subunit vaccines.
Source: Batavia Biosciences
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
